Actinium 225-J591 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Actinium 225-J591 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether Actinium 225-J591 can convert its Radiolabeled antibody, Therapeutic radiopharmaceuticals profile and PSMA biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Actinium 225-J591 (query alias: Actinium 225-J591) |
|---|---|
| Modality / target | Radiolabeled antibody, Therapeutic radiopharmaceuticals; PSMA; PSMA inhibitors |
| Highest global status | Phase 2 |
| Originator | Convergent Therapeutics, Inc. |
| Active developers | Weill Medical College of Cornell University, Merck Sharp & Dohme Corp., Convergent Therapeutics, Inc. |
The MCP disease footprint includes PSMA-Positive Castration-Resistant Prostatic Cancer, Adenocarcinoma of prostate, Metastatic castration-resistant prostate cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06549465 | Phase 2 | Recruiting | 93 | Primary endpoint not disclosed in English source |
| NCT05567770 | Phase 1 | Withdrawn | 0 | Primary endpoint not disclosed in English source |
| NCT04946370 | Phase 1/2 | Recruiting | 52 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Patient-reported outcomes (PRO) from a dose-escalation and expansion trial of fractionated and multiple-cycle PSMA-targeted alpha radionuclide 225Ac-J591.
Phase 1; n=60; evaluation: Positive. Reported fields: FACT-RNT = 49.0 Point ; FACT-P = 74.0 Point
2396P - Dose-escalation + expansion trial of fractionated and multiple-dose PSMA-targeted alpha radionuclide 225Ac-J591 for mCRPC
Phase 1; n=60; evaluation: Positive. Reported fields: DLT = In FD cohort, 1 DLT at 50 KBq/Kg (Gr 4 thrombocytopenia [TCP]), 2 DLTs at 65 KBq (Gr2 TCP >2 wks, Gr4 TCP), 1 DLT at 60 KBq (Gr4 TCP). In MD cohort, 2 DLT at 65 KBq/Kg (Gr1 & Gr3 TCP), 3 DLT at 55 KBq (1 Gr3 & 2 Gr4 TCP), 2 DLT at 45 KBq (Gr1 & Gr2 TCP). ; DLT = In FD cohort, 1 DLT at 50 KBq/Kg (Gr 4 thrombocytopenia [TCP]), 2 DLTs at 65 KBq (Gr2 TCP >2 wks, Gr4 TCP), 1 DLT at 60 KBq (Gr4 TCP). In MD cohort, 2 DLT at 65 KBq/Kg (Gr1 & Gr3 TCP), 3 DLT at 55 KBq (1 Gr3 & 2 Gr4 TCP), 2 DLT at 45 KBq (Gr1 & Gr2 TCP).
Mature phase 1 follow up of alpha emitter 225Ac-J591 with 177Lu-PSMA-I&T in advanced prostate cancer.
Phase 1; n=18; evaluation: Positive. Reported fields: RP2D = 35 KGBq/kg
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Actinium 225-J591 addresses PSMA-Positive Castration-Resistant Prostatic Cancer, Adenocarcinoma of prostate, Metastatic castration-resistant prostate cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Radiolabeled antibody, Therapeutic radiopharmaceuticals—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 1 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2021-09-14 | Convergent and POINT Biopharma will assess the effectiveness of combining CONV 01-α with PNT-2002 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). | Phase 1/2 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “PSMA radiopharmaceutical conjugate and uses thereof”. The milestone feed surfaced a patent-application signal described as “Radiotherapeutic conjugates for treating cancer”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Clinical differentiation versus current standards and pipeline competitors
- Safety, dose optimization, and long-term tolerability
- Patent scope, territorial rights, manufacturing, and commercial positioning
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-16. Counts and status fields may change as source records update.
